9 Meters Biopharma Inc expected to post a loss of 78 cents a share - Earnings Preview

9 Meters Biopharma

12/05/2023 13:39

* 9 Meters Biopharma Inc  NMTR.OQ   NMTR.O  is expected
to show no
change in quarterly revenue when it reports  results on May 15
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for 9 Meters Biopharma
Inc is
for a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 10.3%
in the last three months. ​
    * Wall Street's median 12-month price target for 9 Meters
Biopharma Inc is $20​, above​ its last closing price of $0.76.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.72       -0.76      -0.92     Missed  -20.7
 Sep. 30 2022  -0.83       -0.82      -0.72     Beat    12.2
 Jun. 30 2022  -0.90       -0.83      -0.80     Beat    4​
 Mar. 31 2022  -0.80       -0.75      -0.80     Missed  -6.7
 ​​Dec.                    -0.72      -0.80     Missed  -11.1
 31 2021                                                
 Sep. 30 2021  -0.89       -0.73      -1.00     Missed  -36.4​
 Jun. 30 2021  -0.60       -0.60      -0.60     Met     0
 Mar. 31 2021  -0.55       -0.55      -0.60     Missed  -9.1
 This summary was machine generated May 12 at 12:39 GMT.  All
figures in US dollars  unless otherwise stated